Topics

Clinical Trials About "ERVEBO Ebola Zaire Vaccine Live Registered Four African" RSS

21:43 EDT 2nd April 2020 | BioPortfolio

We list hundreds of Clinical Trials about "ERVEBO Ebola Zaire Vaccine Live Registered Four African" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "ERVEBO Ebola Zaire Vaccine Live Registered Four African" on BioPortfolio

We have published hundreds of ERVEBO Ebola Zaire Vaccine Live Registered Four African news stories on BioPortfolio along with dozens of ERVEBO Ebola Zaire Vaccine Live Registered Four African Clinical Trials and PubMed Articles about ERVEBO Ebola Zaire Vaccine Live Registered Four African for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ERVEBO Ebola Zaire Vaccine Live Registered Four African Companies in our database. You can also find out about relevant ERVEBO Ebola Zaire Vaccine Live Registered Four African Drugs and Medications on this site too.

Showing "ERVEBO Ebola Zaire Vaccine Live Registered Four African" Clinical Trials 1–25 of 6,600+

Extremely Relevant

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.


A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain, with GP homology of the gene was only 97.6%, compared to the GP gene of the strain in 1976. This investigational Ad5-EBOV vaccine was developed according to the 2014 epidemic Zaire strain and formulated as freeze-dry products which could be stored at 4...

A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain, with GP homology of the gene was only 97.6%, compared to the GP gene of the strain in 1976. This investigational Ad5-EBOV vaccine was developed according to the 2014 epidemic Zaire strain and formulated as freeze-dry products which could be stored at 4...


A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

The purpose of this study is to assess the safety and immunogenicity of the investigational ChAd3-EBO-Z vaccine administered to approximately 3 000 adults in Africa as a single IM dose Considering the risk of exposure to Ebola and the potential (based on animal data) for the investigational ChAd3-EBO-Z vaccine to afford at least partial protection, all subjects in the study will receive the investigational ChAd3-EBO-Z vaccine. The subjects in the Group EBO-Z will receive the va...

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

This initial, proof of concept study will focus on identifying significant differences in response to the Ebolavirus Zaire vaccine (ChAd3-EBO-Z) when administered with placebo, MVA-BN-Filo, or ChAd3-EBO-Z boosters after 8 days. All 60 participants will receive the ChAd3-EBO-Z vaccine and then randomized into each booster group (20 receiving each type of booster). Subjects will be followed-up for 6 months to monitor for safety outcomes and efficacy measures. There is no formal h...

R3470-3471-3479 Expanded Access Protocol (EAP) for Treatment of Ebola

Provide individual access to treatment for Zaire Ebola virus disease (EVD) or post-exposure prophylaxis after high-risk exposure to Zaire ebolavirus (EBOV) with the investigational product, REGN3470-3471-3479, a cocktail of human monoclonal antibodies against Ebola glycoprotein.

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.

Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

Background: The Ebola virus causes a severe disease. It can be fatal. The usual incubation period after being exposed is 2 to 21 days. There is no approved treatment for Ebola infection. There is also no vaccine to prevent infection either before or after exposure. Researchers want to test an Ebola vaccine. They want to give it to people before they are exposed to the virus in order to prevent the disease. Objectives: To see how long-lasting and effective the vac...

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the ChAd3 EBO-Z vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately Considering the risk of exposure to Ebola and the potential (based on animal data) for the investigational ChAd3-EBO-Z vaccine to afford at least partial protection, all children in the study will receive the investigational ChAd3 EBO-Z vaccine. The children in the Group EBO-Z/ MENACWY-T...

Evaluating an Ebola and a Margurg Vaccine in Uganda

This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who receive them.

Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination

This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z. Two groups of volunteers will be vaccinated with both vaccines one after the other in a prime/boost regimen. All ChAd3-EBO Z doses are 2.5 x 10^10 - 3.7 x 10^10 vp and all MVA-EBO Z doses are 1.0 x 10^8 pfu. All volunteers will receive a ChAd3-EBO Z priming vaccine and a MVA-EBO Z boosting vaccine 7 days later. The site of administ...

Ebola and Marburg Virus Vaccines

This study will determine if experimental vaccines to prevent Ebola virus infection and Marburg virus infection are safe and what side effects, if any, they cause. Ebola virus infection may range from mild to severe, and may cause breathing problems, severe bleeding, kidney problems and shock that can lead to death. Marburg virus infection causes an illness similar to that caused by the Ebola virus. The vaccines used in this study contain genetic material produced in the labora...

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

This is a Phase I, open-label study to examine safety, tolerability and immunogenicity of an investigational Ebola vaccine given by intramuscular (IM) injection to healthy adults. The study is a dose escalation of VRC-EBOADC086-00-VP, a chimpanzee adenovirus serotype 3 vector vaccine, which encodes wild type (WT) glycoprotein (GP) from the Sudan strain of Ebolavirus.

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults Aged Between 18 and 50 years in Sierra Leone.

Persistence of the Immune Response After Ebola Vaccine Immunisation

The Oxford University is undertaking a follow-on study to a Phase 1 study involving the two viral vectored Ebola vaccines Ad26-ZEBOV and MVA-BN-Filo. The aim of this study is to investigate the persistence of the vaccine induced immune response, 24 months after administration of the primary vaccination.

A Study to Assess a New Ebola Vaccine, cAd3-EBO Z

The purpose of this study is to assess a new Ebola vaccine, cAd3-EBO Z, at different doses. The study will enable us to assess the safety of the vaccine and the extent of the immune response in healthy volunteers. The investigators will do this by giving volunteers a single vaccination, doing blood tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use this vaccine in humans. The investigators plan to recruit a total of ...

Experimental Vaccine for Prevention of Ebola Virus Infection

This study will determine if an experimental vaccine to prevent Ebola virus infection is safe and what side effects, if any, it causes. Ebola virus infection may range from mild to severe, and may cause breathing problems, severe bleeding, kidney problems and shock that can lead to death. The vaccine used in this study contains man-made genetic material similar to one part of the Ebola virus, which is designed to stimulate an immune response to the virus. The vaccine itself can...

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of the HPIV3-EbovZ GP Ebola vaccine candidate in healthy adults.

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO-Z and Ad26.ZEBOV. Four groups of volunteers will be vaccinated with both vaccines one after the other in a prime/boost regimen. All ChAd3-EBO-Z doses are 1x10^11 vp and all Ad26.ZEBOV doses are 5x10^10 vp. Group 1 will receive a ChAd3-EBO-Z priming vaccine and an Ad26.ZEBOV boosting vaccine 28 days later. Group 2 will receive an Ad26.ZEBOV priming vaccin...

STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)

The 2014 outbreak of Ebola in West Africa is the largest in recorded history with widespread and intense transmission in Guinea, Liberia, and Sierra Leone. The high infectivity of blood and secretions, lack of appropriate personal protective equipment (PPE) and challenges in following infection control and prevention protocols put healthcare workers at high risk during outbreaks, and direct contact with the bodies of deceased Ebola victims can also sustain community transmissio...

Ebola Vaccine Trial (Ad26.ZEBOV/MVA-BN-Filo)

An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Background: - Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever. Researchers want to develop a vaccine to prevent Ebola infection. It is impossible for someone to get an Ebola infection from this vaccine. Objectives: - To see if an Ebola vaccine is safe and to study immune responses to it. Eligibility: - Healthy...

Partnership for Research on Ebola VACcinations

The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

This Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care workers) who may be exposed to Ebola in the event of a future outbreak in the Democratic Republic of the Congo (DRC). This study will enhance the immunogenicity database by investigating the kinetics of the humoral immune response. The study will contribute...


More From BioPortfolio on "ERVEBO Ebola Zaire Vaccine Live Registered Four African"

Quick Search